Bruk av medikamenter for alkoholbrukslidelser i Norge 2004–16

Heldal, Anne Taraldsen; Lobmaier, Philipp; Vederhus, John‐Kåre; Bramness, Jørgen G.

doi:10.4045/tidsskr.18.0383

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes over time in the number of registrations may be due to changes in disease prevalence, although changes in factors such as disease-specific guidelines, reimbursement schemes, coding practices, access to the health services, propensity to seek treatment, and marketing of new drugs (e.g. a new opioid antagonist drug with hope for a better drug treatment of alcohol use disorder 31 ) may play a role. Therefore, NCD occurrence in registries is partly influenced by other factors than disease prevalence and must be interpreted with cautione.g.…”

Section: Discussionmentioning

confidence: 99%

“…The low number of individuals registered in NorPD (29%) may reflect that most SUD are not treated with drugs. The sharp increase in NorPD between 2012 and 2013 was due to the marketing of nalmefene (Selincro ® ), an opioid antagonist 31 . The number of individuals diagnosed annually with SUD in NPR increased from 26 000 to 45 000 during the observation period.…”

Section: Substance Use Disorders (Sud)mentioning

confidence: 99%

See 1 more Smart Citation

National health registries – a ‘goldmine’ for studying non-communicable disease occurrence in Norway – the NCDNOR project

NYSTAD,

HJELLVIK,

LARSEN

et al. 2023

Scand J Public Health

View full text Add to dashboard Cite

To estimate occurrence of non-communicable diseases (NCDs) over the life-course in the Norwegian population, national health registries are a vital source of information since they fully represent the entire non-institutionalised population. However, as they are mainly established for administrative purposes, more knowledge about how NCDs are recorded in the registries is needed. To establish this, we begin by counting the number of individuals registered annually with one or more NCDs in any of the registries. The study population includes all inhabitants who lived in Norway from 2004 to 2020 ( N~6.4m). The NCD outcomes are diabetes, cardiovascular diseases, chronic obstructive lung diseases, cancer and mental disorders/substance use disorders. Further, we included hip fractures in our NCD concept. The data sources used to identify individuals with NCDs, including detailed information on diagnoses in primary and secondary health care and dispensings of prescription drugs, are the Cancer Registry of Norway, The Norwegian Patient Registry, The Norwegian Control and Payment of Health Reimbursement database, and The Norwegian Prescription Database. The number of individuals registered annually with an NCD diagnosis and/or a dispensed NCD drug increased over the study period. Changes over time may reflect changes in disease incidence and prevalence, but also changes in disease-specific guidelines, reimbursement schemes and access to and use of health services. Data from more than one health registry to identify individuals with NCDs are needed since the registries reflect different levels of health care services and therefore may reflect disease severity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Substance Use Disorders (Sud)mentioning

confidence: 99%

National health registries – a ‘goldmine’ for studying non-communicable disease occurrence in Norway – the NCDNOR project

NYSTAD,

HJELLVIK,

LARSEN

et al. 2023

Scand J Public Health

View full text Add to dashboard Cite

show abstract

“…DSF has been used as an alcohol deterrent for >60 years by inhibiting the enzyme acetaldehyde dehydrogenase; it functions by breaking down the acetaldehyde generated from enzymatic degradation of alcohol, producing an intense discomfort to alcohol consumers (137). DSF has received particular attention for its antineoplastic effects, both as a single agent and in combination (138).…”

Section: Disulfiram (Dsf)mentioning

confidence: 99%

New drugs are not enough‑drug repositioning in oncology: An update

Armando

Gómez

2020

Int J Oncol

View full text Add to dashboard Cite

Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.

show abstract

The use of medications approved for alcohol use disorders in Italy

Fortinguerra

Pierantozzi²,

Trotta³

2023

Front. Public Health

View full text Add to dashboard Cite

BackgroundItaly has the highest per capita alcohol consumption among European countries. Several pharmacological treatments for alcohol use disorders (AUDs) are currently available in Italy, but no consumption data are available. A first analysis of national drug consumption, comprising the whole Italian population over a long-term period covering the COVID-19 pandemic, was performed.MethodsTo analyze the consumption of medications indicated for therapy of alcohol dependence, different national data sources were used. Consumption was measured as a defined daily dose (DDD) per 1,000,000 inhabitants per day.ResultsIn 2020, the total consumption of medicines used in the treatment of AUDs amounted to 310.3 DDD per 1 million inhabitants per day (0.018% of the overall drug consumption in Italy) with a decreasing gradient from the north (373.9 DDD) to the south (250.7 DDD). 53.2% of the overall doses were dispensed by public healthcare facilities and 23.5% by community pharmacies, while the remaining 23.3% were purchased privately. The temporal trend of consumption seemed to be stable across the last few years, although an impact of the COVID-19 pandemic was observed. Disulfiram was the most consumed medicine over years.ConclusionAll Italian regions offer pharmacological treatments to patients with AUDs, but differences in the number of dispensed doses suggest a different local organization of patient care, which can be partly explained by the different severity of the clinical condition of residing patients. Pharmacotherapy of alcoholism should be deeply investigated to describe the clinical characteristics of treated patients (i.e., comorbidities) and evaluate the appropriateness of prescribed medications.

show abstract

Bruk av medikamenter for alkoholbrukslidelser i Norge 2004–16

Cited by 3 publications

References 21 publications

National health registries – a ‘goldmine’ for studying non-communicable disease occurrence in Norway – the NCDNOR project

National health registries – a ‘goldmine’ for studying non-communicable disease occurrence in Norway – the NCDNOR project

New drugs are not enough‑drug repositioning in oncology: An update

The use of medications approved for alcohol use disorders in Italy

Contact Info

Product

Resources

About